Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

video_2_edelbaum-mp4

October 8, 2018October 8, 2018

Published by

View all posts by

Published October 8, 2018October 8, 2018

Post navigation

Previous Post video_2_edelbaum-mp4

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Celltrion’s Adalimumab Biosimilar Yuflyma® Receives FDA Approval May 25, 2023
Amgen Settles With J&J: Its Ustekinumab Biosimilar to Launch by Jan 1, 2025 May 24, 2023
Why Aren’t There More Patent Cases Pending, Considering the Size of the Biosimilar Pipeline? May 15, 2023
A Conversation with Thomas Nusbickel, Chief Commercial Officer, Senior VP, Celltrion USA May 11, 2023
Prospective Biosimilar Maker Lannett Files Chapter 11 Bankruptcy May 4, 2023
First-Quarter Sales of Adalimumab Reveal Plenty of Savings, but Little Early Revenue for Amgen April 28, 2023
A Conversation With Sarfaraz K. Niazi, PhD: Part 2 April 17, 2023
The Drug Industry Rightly Fears Judicial Overreach April 13, 2023
A Conversation With Sarfaraz K. Niazi, PhD: Part 1 April 11, 2023
Biosimilar Bytes April 6, 2023

Recent Comments

	Celltrion's Pen… on The Implications of Celltrion’…
	40th Biosimilar Appr… on FDA Approves Fresenius Kabi’s…
	Biogen Announces Sub… on Tocilizumab Biosimilars Approa…
	J&J Slaps Patent… on Ustekinumab Biosimilars Update
	J&J Slaps Patent… on Preliminary Phase 3 Study Data…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
Amgen Settles With J&J: Its Ustekinumab Biosimilar to Launch by Jan 1, 2025
Celltrion’s Adalimumab Biosimilar Yuflyma® Receives FDA Approval
Hulio
Zarxio
Nivestym
Is Differential Cost Sharing an Incentive for Biosimilar Uptake in Commercial Patients?
Tocilizumab Biosimilars Approaching: Developments on Three Fronts
Alvotech’s Ustekinumab Biosimilar Application With the FDA: Decision Expected Before End of Year
A Conversation with Thomas Nusbickel, Chief Commercial Officer, Senior VP, Celltrion USA

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.